… Massachusetts, USA. At ProQR, we are on a mission to edit RNA, treat disease, and change lives. A team of 180+ … of the communities we serve. Our proprietary Axiomer™ RNAediting technology platform enables the editing of …
… Massachusetts, USA. At ProQR, we are on a mission to edit RNA, treat disease and change lives. A team of 180+ … of the communities we serve. Our proprietary Axiomer™ RNAediting technology platform enables the editing of …
… Massachusetts, USA. At ProQR, we are on a mission to edit RNA, treat disease and change lives. A team of 180+ … of the communities we serve. Our proprietary Axiomer™ RNAediting technology platform enables the editing of …
… Massachusetts, USA. At ProQR, we are on a mission to edit RNA, treat disease and change lives. A team of 180+ … of the communities we serve. Our proprietary Axiomer™ RNAediting technology platform enables the editing of …
Chardan’s 9th Annual Genetic Medicines Conference – October 21, 2025
Company management will participate in an RNA Editing panel at 1:00 p.m. ET and will conduct 1x1 investor meetings in conjunction with the conference.
ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
ProQR will present new preclinical data for Axiomer, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the ASGCT Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.
